Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Tubulis GmbH, a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments.
We are extremely proud to have been among the first investors since the initial funding round in 2020 and to have been able to support the company’s rapid growth ever since.
This accomplishment demonstrates what is possible when outstanding science is combined with the extraordinary dedication of a strong team. We hope Tubulis’ groundbreaking treatments will be launched soon so that they can help as many patients as possible.
Congratulations and kudos to Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Charles Fuchs, Dr. Björn Hock, Dr. Matthew Norkunas, Halley Gilbert, JD, and the entire Tubulis team!
Further information can be found in the press release at the following link
More about Tubulis
